Clinical Trials | May 07, 2026
GRIN Therapeutics launches Phase 3 beeline study in Europe for radiprodil in GRIN-NDD
This is an exciting and meaningful milestone for GRIN Therapeutics
This is an exciting and meaningful milestone for GRIN Therapeutics
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The company also announced a major portfolio shift, planning to divest its Immunodiagnostics business in China, a unit that generated approximately 6% of its fiscal 2025 revenue
The platform offers personalised recovery plans, AI-driven movement tracking, and access to certified physiotherapists for more than 250 conditions
Conceptualized as an aggregator platform it integrates existing programme systems through an API-based federated architecture
Precision medicine company advances Raman spectroscopy-based therapeutic drug monitoring platform for rapid, patient-specific dosing solutions
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Workshop focused on strengthening sterile processing standards, infection prevention, and CSSD best practices in healthcare settings
Early implementation of West Synchrony S1 platform aims to accelerate biologics and vaccine development while reducing manufacturing risk for biopharma partners
The company’s Growth Portfolio delivered $6.2 billion in revenue
Subscribe To Our Newsletter & Stay Updated
